We are live on
!
Find out more
IHM
Iguana Healthcare Management Portfolio holdings
AUM
$152M
1-Year Est. Return
48.74%
This Fund
S&P 500
This Quarter
Est. Return
+9.67%
1 Year Est. Return
+48.74%
3 Year Est. Return
+142.13%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$246M
AUM Growth
-$27.1M
(-9.9%)
Cap. Flow
-$37.7M
Cap. Flow
% of AUM
-15.33%
Top 10 Holdings %
Top 10 Hldgs %
36.95%
Holding
116
New
41
Increased
15
Reduced
17
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$10.8M |
| 2 |
Elevance Health
ELV
|
+$9.58M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$7.09M |
| 4 |
Gilead Sciences
GILD
|
+$4.44M |
| 5 |
Illumina
ILMN
|
+$3.65M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$14.5M |
| 2 |
Cigna
CI
|
+$13.2M |
| 3 |
Medtronic
MDT
|
+$7.5M |
| 4 |
Baxter International
BAX
|
+$6.8M |
| 5 |
Eli Lilly
LLY
|
+$5.65M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.04% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ADMS
51
DELISTED
Adamas Pharmaceuticals
ADMS
| $1.51M | 0.62% |
100,000
-100,000
| -50% | -$1.65M |
|
|
SAGE
52
CALL
DELISTED
Sage Therapeutics
SAGE
| $1.51M | 0.61% |
+50,000
| New | +$1.67M |
|
53
Seres Therapeutics
MCRB
$46.6M
| $1.45M | 0.59% |
+2,500
| New | +$1.47M |
|
54
Cytokinetics
CYTK
$10.6B
| $1.42M | 0.58% |
150,000
-25,000
| -14% | -$205K |
|
|
AGTC
55
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $1.41M | 0.57% |
100,000
| – | – |
|
56
CALL
Alnylam Pharmaceuticals
ALNY
$29.6B
| $1.39M | 0.56% |
+25,000
| New | +$1.58M |
|
|
57
Alnylam Pharmaceuticals
ALNY
$29.6B
| $1.39M | 0.56% |
25,000
-35,000
| -58% | -$2.21M |
|
|
RVNC
58
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.36M | 0.55% |
+100,000
| New | +$1.77M |
|
59
Tandem Diabetes Care
TNDM
$1.63B
| $1.32M | 0.54% |
17,500
+2,500
| +17% | +$201K |
|
60
Alkermes
ALKS
$8.26B
| $1.3M | 0.53% |
+30,000
| New | +$1.24M |
|
61
Minerva Neurosciences
NERV
$206M
| $1.28M | 0.52% |
+15,625
| New | +$993K |
|
62
Coherus Oncology
CHRS
$187M
| $1.27M | 0.52% |
75,000
-25,000
| -25% | -$469K |
|
|
WBA
63
DELISTED
Walgreens Boots Alliance
WBA
| $1.25M | 0.51% |
+15,000
| New | +$1.21M |
|
|
CLVS
64
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.24M | 0.5% |
+90,000
| New | +$1.32M |
|
65
Viatris
VTRS
$18.7B
| $1.08M | 0.44% |
+25,000
| New | +$1.11M |
|
|
ITCI
66
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $971K | 0.4% |
25,000
-25,000
| -50% | -$898K |
|
|
AVDL
67
DELISTED
Avadel Pharmaceuticals
AVDL
| $806K | 0.33% |
+75,000
| New | +$800K |
|
68
ADMA Biologics
ADMA
$2.22B
| $744K | 0.3% |
+125,000
| New | +$875K |
|
|
69
PUT
Seres Therapeutics
MCRB
$46.6M
| $726K | 0.3% |
+1,250
| New | +$733K |
|
|
SGMO
70
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $724K | 0.29% |
125,000
+50,000
| +67% | +$319K |
|
71
Pacific Biosciences
PACB
$354M
| $704K | 0.29% |
100,000
+25,000
| +33% | +$228K |
|
|
CCXI
72
DELISTED
ChemoCentryx, Inc.
CCXI
| $674K | 0.27% |
+150,000
| New | +$563K |
|
|
GI
73
DELISTED
EndoChoice Holdings, Inc.
GI
| $613K | 0.25% |
125,000
+10,000
| +9% | +$47.7K |
|
|
MDVN
74
DELISTED
MEDIVATION, INC.
MDVN
| $603K | 0.25% |
10,000
-255,000
| -96% | -$14.5M |
|
|
CLSD
75
DELISTED
Clearside Biomedical
CLSD
| $526K | 0.21% |
+5,001
| New | +$524K |
|
Similar funds
HWP
PAM
USG2
LCM
FPF
FIAS
CII
OPWM
Iguana Healthcare Management's Q2 2016 Portfolio in Review
As of Q2 2016, Iguana Healthcare Management held 116 positions worth $246M, down 9.9% from $273M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Iguana Healthcare Management withdrew a net $37.7M in Q2 2016, closing 34 positions and reducing 17 holdings. Its most notable exit was Cigna, an estimated $13.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 68% a quarter earlier, followed by Industrials.
Against the trend, Iguana Healthcare Management opened a new position in Shire pic worth $11M.
- Iguana Healthcare Management's largest Q2 2016 buy was Shire pic: 60,000 shares worth $11M.
- Iguana Healthcare Management added most to Gilead Sciences in Q2 2016, an estimated $4.44M increase.
- Iguana Healthcare Management's biggest Q2 2016 reduction was MEDIVATION, INC., cutting an estimated $14.5M.
- Iguana Healthcare Management fully exited Cigna in Q2 2016, selling an estimated $13.2M.
- Iguana Healthcare Management's ten largest holdings make up 37% of its $246M portfolio in Q2 2016.
- Iguana Healthcare Management opened 41 new positions and closed 34 in Q2 2016.
- Iguana Healthcare Management's portfolio value fell 9.9% quarter-over-quarter to $246M.
Based on Iguana Healthcare Management's 13F filing for Q2 2016, filed 15 Aug 2016.